Impact of COVID-19 Vaccines on Cerebrovascular Health

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
StrokeStroke, AcuteStroke, IschemicDementiaBrain IschemiaAlzheimer DiseaseBrain DiseasesMajor Adverse Cardiovascular EventArterial ThromboembolismVenous Thromboembolism
Interventions
DIAGNOSTIC_TEST

Laboratory tests and Montreal Cognitive Assessment

Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.

DIAGNOSTIC_TEST

Laboratory tests and Montreal Cognitive Assessment

Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.

Trial Locations (1)

Unknown

RECRUITING

Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER